UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2018

Commission File Number 001-38079

 

 

UROGEN PHARMA LTD.

(Translation of registrant’s name into English)

 

 

9 Ha’Ta’asiya Street

Ra’anana 4365007, Israel

(Address of Principal Executive Offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-For Form 40-F:

Form 20-F  ☒             Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

 

 

 

---

UroGen Pharma Ltd.

On June 4, 2018, UroGen Pharma Ltd. (the “Company”) held an annual meeting of shareholders (the “Meeting”). The proxy statement for the Meeting was filed by the Company with the Securities and Exchange Commission as an exhibit to its Report on Form 6-K on April 25, 2018 (File No. 001-38079) and is incorporated herein by reference. All Proposals 1 through 3 brought before the shareholders at the Meeting were approved by the shareholders.

---

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

				UROGEN PHARMA LTD.
Date: June 6, 2018				By:		/s/ Ron Bentsur
						Ron Bentsur
						Chief Executive Officer